

# Monitoring Worksheet for Patients on Second-Generation Antipsychotics\*

Patient Name \_\_\_\_\_

Medication prescribed \_\_\_\_\_ Date Started \_\_\_\_\_ Date Discontinued \_\_\_\_\_

Medication prescribed \_\_\_\_\_ Date Started \_\_\_\_\_ Date Discontinued \_\_\_\_\_

Medication prescribed \_\_\_\_\_ Date Started \_\_\_\_\_ Date Discontinued \_\_\_\_\_

Medication prescribed \_\_\_\_\_ Date Started \_\_\_\_\_ Date Discontinued \_\_\_\_\_

Medication prescribed \_\_\_\_\_ Date Started \_\_\_\_\_ Date Discontinued \_\_\_\_\_

Medication prescribed \_\_\_\_\_ Date Started \_\_\_\_\_ Date Discontinued \_\_\_\_\_

## Personal and family history (Baseline, annually)

Patint history	Family history	Disease	Notes
<input type="checkbox"/>	<input type="checkbox"/>	Obesity	_____
<input type="checkbox"/>	<input type="checkbox"/>	Diabetes	_____
<input type="checkbox"/>	<input type="checkbox"/>	Dyslipidemia	_____
<input type="checkbox"/>	<input type="checkbox"/>	Hypertension	_____
<input type="checkbox"/>	<input type="checkbox"/>	Cardiovascular Disease	_____

## Weight (BMI) (Baseline + every visit for 6 months after medication initiation)

Date								

## Waist circumference – measure at level of umbilicus (Baseline + annually)

Date								

## Blood Pressure (Baseline + 12 weeks + annually)

Date								

## Fasting Plasma Glucose (Baseline + 12 weeks + annually)

Date								

## Fasting Lipid Profile (Baseline + 12 weeks + every 5 years)

Date								

\* ADA. Diabetes Care. 2004;27(2):596-601.

# Recommendations for Screening and Monitoring

## FDA Recommendations for Monitoring Patients Treated With Atypical Antipsychotics

Patient with pre-existing diabetes	Patients with risk factors for diabetes	All patients initiated on an atypical antipsychotic
<ul style="list-style-type: none"> <li>Monitor regularly for worsening of glucose control</li> </ul>	<ul style="list-style-type: none"> <li>Fasting blood glucose at baseline then periodically during treatment</li> </ul>	<ul style="list-style-type: none"> <li>Monitor for symptoms of hyperglycemia (polydipsia, polyphagia, and weakness)</li> <li>Fasting blood glucose in patients who develop symptoms of diabetes</li> </ul>

Source: Food and Drug Administration recommendations for atypical antipsychotics, September 2003.

## ADA Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

Monitoring protocol for patients on second-generation antipsychotics.  
More frequent assessments may be warranted based on clinical studies.

	Baseline	4 Weeks	8 Weeks	12 Weeks	Quarterly	Annually	Every 5 Years
Personal/family history	X					X	
Weight (BMI)	X	X	X	X	X		
Waist circumference	X					X	
Blood pressure	X			X		X	
Fasting plasma glucose	X			X		X	
Fasting lipid profile	X			X			X

Source: ADA. Diabetes Care. 2004;27(2):596-601.